Indication
Biliary tract malignancy
Biliary tract malignancy refers to a heterogeneous group of aggressive epithelial cancers affecting the hepatobiliary ductal system, including intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampulla of Vater carcinoma. Read more about Biliary tract malignancy
54 drugs 36 manufacturers
Drugs that treat it
Common Biliary tract malignancy therapies.
GEMCITABINE HCL
GEMCITABINE HCL
GEMCITABINE HCL
GEMCITABINE HCL
CISPLATIN
GEMCITABINE HCL
GEMCITABINE HCL
KEYTRUDA POWDER (pembrolizumab)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonBiliary tract malignancy refers to a heterogeneous group of aggressive epithelial cancers affecting the hepatobiliary ductal system, including intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampulla of Vater carcinoma.
Pathophysiologically, these malignancies predominantly arise from the epithelial lining of the bile ducts and gallbladder, frequently driven by chronic biliary inflammation, cholestasis, or genetic alterations.
Because early lesions are typically asymptomatic, patients often present at advanced or metastatic stages with clinical features of mechanical biliary obstruction, such as painless jaundice, pruritus, dark urine, acholic stools, abdominal pain, and unexplained weight loss.
- nih.gov
Biliary tract malignancy refers to a heterogeneous group of aggressive epithelial cancers affecting the hepatobiliary ductal system, including intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampulla of Vater carcinoma
- cancer.gov
Biliary tract malignancy refers to a heterogeneous group of aggressive epithelial cancers affecting the hepatobiliary ductal system, including intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampulla of Vater carcinoma Because early lesions are typically asymptomatic, patients often present at advanced or metastatic stages with clinical features of mechanical biliary obstruction, such as painless jaundice, pruritus, dark urine, acholic stools, abdominal pain, and unex...
- nih.gov
Biliary tract malignancy refers to a heterogeneous group of aggressive epithelial cancers affecting the hepatobiliary ductal system, including intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampulla of Vater carcinoma Pathophysiologically, these malignancies predominantly arise from the epithelial lining of the bile ducts and gallbladder, frequently driven by chronic biliary inflammation, cholestasis, or genetic alterations
- nih.gov
Pathophysiologically, these malignancies predominantly arise from the epithelial lining of the bile ducts and gallbladder, frequently driven by chronic biliary inflammation, cholestasis, or genetic alterations
- nih.gov
Pathophysiologically, these malignancies predominantly arise from the epithelial lining of the bile ducts and gallbladder, frequently driven by chronic biliary inflammation, cholestasis, or genetic alterations
- clevelandclinic.org
Because early lesions are typically asymptomatic, patients often present at advanced or metastatic stages with clinical features of mechanical biliary obstruction, such as painless jaundice, pruritus, dark urine, acholic stools, abdominal pain, and unexplained weight loss
- ucsf.edu
Because early lesions are typically asymptomatic, patients often present at advanced or metastatic stages with clinical features of mechanical biliary obstruction, such as painless jaundice, pruritus, dark urine, acholic stools, abdominal pain, and unexplained weight loss
- jhu.edu
Because early lesions are typically asymptomatic, patients often present at advanced or metastatic stages with clinical features of mechanical biliary obstruction, such as painless jaundice, pruritus, dark urine, acholic stools, abdominal pain, and unexplained weight loss
Personalize your experience
Follow Biliary tract malignancy and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.